|
|
| Zeile 1: |
Zeile 1: |
| | {{up|PHA Biologicals}} | | {{up|PHA Biologicals}} |
| | + | {{qt|Colchicine}} |
| | | | |
| − |
| |
| − | colchicine as inh. of the inflammosome
| |
| − |
| |
| − | {{tp|p=32337546|t=ä. Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?|pdf=|usr=}}
| |
| − | {{tp|p=32251729|t=ä. The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design |pdf=|usr=}}
| |
| − | {{tp|p=32344275|t=2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |pdf=|usr=}}
| |
| − | {{tp|p=32380315|t=2020. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis |pdf=|usr=}}
| |
| − | {{tp|p=32472681|t=2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.|pdf=|usr=007}}
| |
| − | {{tp|p=32445400|t=2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?|pdf=|usr=007}}
| |
| − | {{tp|p=32511763|t=2020. Colchicine and COVID-19.|pdf=|usr=007}}
| |
| − | {{tp|p=32503853|t=2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?|pdf=|usr=007}}
| |
| − | {{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
| |
| − | {{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
| |
| − | {{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
| |
| − | {{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=010}}
| |
| − | {{tp|p=32492478|t=2020. Treating COVID-19 with colchicine in community healthcare setting.|pdf=|usr=011}}
| |
| − | {{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=010}}
| |
| − | {{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=010}}
| |
| − | {{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=010}}
| |
| − | {{tp|p=32394215|t=2020. Colchicine may not be effective in COVID-19 infection; it may even be harmful?|pdf=|usr=011}}
| |
| − | {{tp|p=32579195|t=2020. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.|pdf=|usr=011}}
| |
| − | {{tp|p=32579190|t=2020. Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?|pdf=|usr=011}}
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | topic
| |
| | {{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}} | | {{ttp|p=32493814|t=2020. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.|pdf=|usr=007}} |
| | {{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}} | | {{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}} |
